Levofloxacin 250MG + Ornidazole 500MG Tablets are a combination solid dosage form that includes two active pharmaceutical ingredients in one tablet. Creating such a combination tablet demands formulation design, precise ingredient measurement, even distribution of both medicines proper compression and thorough quality checks. For companies looking to grow their line of combination oral medicines this tablet can also be part of a structured PCD Pharma Franchise plan.
The tablet contains Levofloxacin 250MG and Ornidazole 500MG along with pharmaceutical-grade excipients. Based on the approved formula the tablet may include diluents, binders, disintegrants, lubricants, glidants and other functional additives. The final group of excipients is chosen after formulation development and compatibility testing.
Formulation work for Levofloxacin 250MG. Ornidazole 500MG Tablets starts with studying the chemical traits of both active ingredients. Since the two components are present in amounts ensuring a uniform mix of each ingredient throughout the powder blend is a key goal.
Diluents are added to achieve the tablet weight and to improve how the powder behaves during processing. Binders help give the tablet strength so it does not break easily. Disintegrants ensure the tablet breaks apart properly inside the body. Lubricants and glidants are used in amounts to help the powder flow smoothly and allow tablets to come out of the machine cleanly.
Pre formulation studies look at particle size, powder flow, sensitivity to moisture, compressibility and how well Levofloxacin, Ornidazole and the selected excipients work together.
The final formulation is fine-tuned through development trials to get the tablet hardness, friability, disintegration time, dissolution rate and overall stability.
Manufacturing begins with weighing and checking of Levofloxacin, Ornidazole and all other ingredients as per the approved batch manufacturing formula.
Raw materials might need preprocessing like sieving or milling when needed. These steps help get particle sizes and better powder flow.
The active ingredients are added into the mixture through a controlled blending process. Because Levofloxacin and Ornidazole are in amounts the order of addition and how they are diluted must be carefully managed to avoid segregation and uneven concentration.
Mixing time sequence of adding materials load on equipment and operating conditions are determined during process development. Samples taken from parts of the blend are tested for uniformity following the approved quality guidelines.
Depending on the chosen manufacturing method the blend may go through compression or a granulation process. Granulated material is checked for moisture content, particle size and flow before being compressed into tablets.
The prepared blend is compressed using tools and under controlled machine settings. Compression force, machine speed and how the powder feeds into the machine affect tablet weight, thickness, hardness and physical integrity.
During compression in-process checks are done at intervals. Average weight and weight variation are monitored to keep consistency across the batch.
Tablet hardness is kept within limits to ensure the tablet can withstand handling, packaging and transportation. At the time compression force is adjusted to maintain good disintegration and dissolution performance.
Friability testing checks how well the tablet resists wear and tear. Visual inspection helps detect any issues like capping, lamination, chipping, sticking or uneven surfaces.
Disintegration and dissolution tests can be included in the product testing based on the approved specification. These tests help confirm that the tablet performs consistently in terms of behavior.
Finished-product quality control ensures that Levofloxacin 250MG + Ornidazole 500MG Tablets meet all approved specifications. Identification and assay of both ingredients are carried out using validated analytical methods.
Testing may include uniformity of dosage units, average weight, weight variation, hardness, thickness, friability, disintegration and dissolution depending on the specification.
Because the medicine has two ingredients the test methods must reliably identify and measure each component in the tablet. Related substances and degradation products may also be checked where necessary.
Stability studies are conducted under storage conditions to track the product over its expected shelf life. Samples are examined periodically for appearance, potency, breakdown profile, dissolution, disintegration and physical properties.
Stability data helps decide the storage conditions and guides the choice of packaging that protects the product during its shelf life.
Packaging selection is a step in developing Levofloxacin 250MG + Ornidazole 500MG Tablets. The packaging must protect against moisture, contamination and physical damage during storage, transport and daily use.
Blister packs, strip packs or other suitable packaging formats can be chosen based on the stability profile and approved packaging standards. Packaging materials are evaluated for compatibility with the formulation and seal integrity is tested to keep the product protected.
The final packaging artwork should show the approved composition, batch number, manufacturing details, storage instructions and other regulatory information. Consistent artwork and packaging rules also support presentation of the product.
For manufacturers and marketers this combination tablet can be a valuable addition to an oral solid-dose product lineup. Raw-material weighing proper blending, optimized compression, analytical testing and stability monitoring are all essential for reliable product development.
For companies building a PCD Pharma Franchise portfolio standardized manufacturing processes, clear quality standards and proper packaging help ensure organized product management and a consistent image, across the pharmaceutical supply chain.
Levofloxacin 250MG + Ornidazole 500MG Tablets with formulation, manufacturing, quality control, stability, packaging and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech